Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

Primary liver cancer is one of the most common malignant tumors in the world, and about 80%\~90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC). Radical surgery is the main method for patients with HCC to obtain long-term survival. However, the early recurrence rate of high-risk HCC is very high, which seriously affects the overall therapeutic effect.

Trial Details

NCT ID
NCT06420440
Phase
PHASE2
Sponsor
Chen Xiaoping
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Hepatic arterial infusion chemotherapy
  • Lenvatinib
  • Tislelizumab
  • Liver resection
Locations (sample)
  • Xiangyang, Hubei, China|32.0422,112.14479
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • Aged 18-75.
  • No previous local or systemic treatment for hepatocellular carcinoma.
  • Child-Pugh liver function score ≤ 7.
  • ECOG PS 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →